INTELLIA THERAPEUTICS, INC. Comprehensive Income
INTELLIA THERAPEUTICS, INC. (NTLA) reported Comprehensive Income of -$107.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$107.42M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$97.50M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$95.74M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$100.99M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$412.27M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$518.29M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$475.99M.
- INTELLIA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$479.01M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$107.42M 10-Q · filed 2026-08-06 | -$204.93M 10-Q · filed 2026-08-06 | -$300.67M derived: sum of 3 quarters · filed 2026-08-06 | -$401.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$97.50M 10-Q · filed 2026-05-11 | -$193.25M derived: sum of 2 quarters · filed 2026-05-11 | -$294.23M derived: sum of 3 quarters · filed 2026-05-11 | -$395.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$95.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$196.73M derived: sum of 2 quarters · filed 2026-02-26 | -$298.39M derived: sum of 3 quarters · filed 2026-08-06 | -$412.27M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$100.99M 10-Q · filed 2025-11-06 | -$202.65M derived: sum of 2 quarters · filed 2026-08-06 | -$316.52M 10-Q · filed 2025-11-06 | -$448.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$101.66M 10-Q · filed 2026-08-06 | -$215.54M 10-Q · filed 2026-08-06 | -$347.13M derived: sum of 3 quarters · filed 2026-08-06 | -$478.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$113.88M 10-Q · filed 2026-05-11 | -$245.47M derived: sum of 2 quarters · filed 2026-05-11 | -$376.73M derived: sum of 3 quarters · filed 2026-05-11 | -$523.91M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$131.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$262.85M derived: sum of 2 quarters · filed 2026-02-26 | -$410.03M derived: sum of 3 quarters · filed 2026-02-26 | -$518.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$131.26M 10-Q · filed 2025-11-06 | -$278.44M derived: sum of 2 quarters · filed 2025-11-06 | -$386.70M 10-Q · filed 2025-11-06 | -$517.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$147.18M 10-Q · filed 2025-08-07 | -$255.44M 10-Q · filed 2025-08-07 | -$386.29M derived: sum of 3 quarters · filed 2026-02-26 | -$508.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$108.26M 10-Q · filed 2025-05-08 | -$239.10M derived: sum of 2 quarters · filed 2026-02-26 | -$361.03M derived: sum of 3 quarters · filed 2026-02-26 | -$485.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$130.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$252.78M derived: sum of 2 quarters · filed 2026-02-26 | -$377.65M derived: sum of 3 quarters · filed 2026-02-26 | -$475.99M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$121.93M 10-Q · filed 2024-11-07 | -$246.80M derived: sum of 2 quarters · filed 2024-11-07 | -$345.14M 10-Q · filed 2024-11-07 | -$456.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$124.87M 10-Q · filed 2024-08-08 | -$223.21M 10-Q · filed 2024-08-08 | -$334.71M derived: sum of 3 quarters · filed 2025-02-27 | -$447.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$98.34M 10-Q · filed 2024-05-09 | -$209.84M derived: sum of 2 quarters · filed 2025-02-27 | -$322.89M derived: sum of 3 quarters · filed 2025-02-27 | -$425.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$111.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$224.54M derived: sum of 2 quarters · filed 2025-02-27 | -$326.71M derived: sum of 3 quarters · filed 2025-02-27 | -$479.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$113.04M 10-Q · filed 2023-11-09 | -$215.21M derived: sum of 2 quarters · filed 2023-11-09 | -$367.51M 10-Q · filed 2023-11-09 | -$451.21M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$102.17M 10-Q · filed 2023-08-03 | -$254.47M 10-Q · filed 2023-08-03 | -$338.17M derived: sum of 3 quarters · filed 2024-02-22 | -$409.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$152.30M 10-Q · filed 2023-05-04 | -$236.00M derived: sum of 2 quarters · filed 2024-02-22 | -$307.80M derived: sum of 3 quarters · filed 2024-02-22 | -$376.61M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$83.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$155.50M derived: sum of 2 quarters · filed 2024-02-22 | -$224.31M derived: sum of 3 quarters · filed 2024-02-22 | -$270.52M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$71.81M 10-Q · filed 2022-11-03 | -$140.61M derived: sum of 2 quarters · filed 2022-11-03 | -$186.83M 10-Q · filed 2022-11-03 | -$229.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$68.81M 10-Q · filed 2022-08-04 | -$115.03M 10-Q · filed 2022-08-04 | -$157.25M derived: sum of 3 quarters · filed 2023-02-23 | -$185.21M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$46.22M 10-Q · filed 2022-05-05 | -$88.44M derived: sum of 2 quarters · filed 2023-02-23 | -$116.40M derived: sum of 3 quarters · filed 2023-02-23 | -$149.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$42.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$70.19M derived: sum of 2 quarters · filed 2023-02-23 | -$102.80M derived: sum of 3 quarters · filed 2023-02-23 | -$134.49M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$27.96M 10-Q · filed 2021-11-04 | -$60.58M derived: sum of 2 quarters · filed 2021-11-04 | -$92.27M 10-Q · filed 2021-11-04 | -$120.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$32.61M 10-Q · filed 2021-08-05 | -$64.31M 10-Q · filed 2021-08-05 | -$92.66M derived: sum of 3 quarters · filed 2022-02-24 | -$116.21M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$31.69M 10-Q · filed 2021-05-06 | -$60.05M derived: sum of 2 quarters · filed 2022-02-24 | -$83.60M derived: sum of 3 quarters · filed 2022-02-24 | -$109.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$28.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$51.90M derived: sum of 2 quarters · filed 2022-02-24 | -$77.39M derived: sum of 3 quarters · filed 2022-02-24 | -$99.24M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$23.55M 10-Q · filed 2020-11-05 | -$49.04M derived: sum of 2 quarters · filed 2020-11-05 | -$70.89M 10-Q · filed 2020-11-05 | -$89.99M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$25.49M 10-Q · filed 2020-08-06 | -$47.34M 10-Q · filed 2020-08-06 | -$66.43M derived: sum of 3 quarters · filed 2021-02-26 | -$89.14M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$21.85M 10-Q · filed 2020-05-07 | -$40.95M derived: sum of 2 quarters · filed 2021-02-26 | -$63.65M derived: sum of 3 quarters · filed 2021-02-26 | -$85.87M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$41.80M derived: sum of 2 quarters · filed 2021-02-26 | -$64.02M derived: sum of 3 quarters · filed 2021-02-26 | -$85.37M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$22.70M 10-Q · filed 2019-10-31 | -$44.92M derived: sum of 2 quarters · filed 2019-10-31 | -$66.28M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$22.22M 10-Q · filed 2019-08-01 | -$43.58M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | -$21.36M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | -$67.54M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$31.63M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |